Trilaciclib for prevention of chemotherapy-induced myelosuppression in lung cancer:a case report and literature review
Lung cancer has the highest morbidity and mortality among malignant tumors in China,and non-small cell lung cancer(NSCLC)is the main pathological type of lung cancer,accounting for approximately 80%to 85%.Currently,platinum-based chemotherapy is still the standard first-line chemotherapy regimen for advanced driver-gene negative NSCLC,and the main adverse event is chemotherapy-induced myelosuppression(CIM),including neutropenia,thrombocytopenia,and anemia.At present,the traditional treatment of CIM have certain limitations,mainly including targeting only mono-lineage,having the risk of inducing other adverse events,long duration of treatment with a slow onset of action,and possibility of bone marrow depletion.As a novel cyclin-dependent kinase 4/6(CDK4/6)inhibitor,trilaciclib plays a significant role in multi-lineage bone marrow protection by inducing transient arrest in G1 phase with high efficiency,selectivity and reversibility.This article reports a patient with NSCLC who receiced trilaciclib for preventing CIM,aiming to provide reference basis for clinical practice.
NETL
NSTL
万方数据
维普
